Huang X H, Liu Z H
National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing 210016, China.
Zhonghua Yi Xue Za Zhi. 2021 Jun 15;101(22):1631-1634. doi: 10.3760/cma.j.cn112137-20210425-00994.
To meet the challenges in the diagnosis and treatment of systemic light chain (AL) amyloidosis, the China Systemic Light Chain Amyloidosis Collaborative Group, together with multidisciplinary experts, developed the "Guideline for the Diagnosis and Treatment of Systemic Light Chain Amyloidosis" in 2016. In order to introduce progress in this field and better guide the clinical practice, the guideline has been updated recently. The in-depth understanding of AL amyloidosis has not only improved the level of diagnosis and treatment of the disease, but also promoted the integration of multiple disciplines, accelerated the development of clinical trials and the improvement of disease diagnosis and treatment modes.
为应对系统性轻链(AL)淀粉样变性诊断和治疗中的挑战,中国系统性轻链淀粉样变性协作组联合多学科专家于2016年制定了《系统性轻链淀粉样变性诊断和治疗指南》。为介绍该领域的进展并更好地指导临床实践,该指南最近进行了更新。对AL淀粉样变性的深入了解不仅提高了该疾病的诊断和治疗水平,还促进了多学科融合,加速了临床试验的发展以及疾病诊断和治疗模式的改进。